1.Anti-SARS-CoV-2 receptor binding domain antibodies after the second dose of Sinovac and AstraZeneca vaccination
Marisca Evalina GONDOKESUMO ; Anita PURNAMAYANTI ; Puri Safitri HANUM ; Winnie Nirmala SANTOSA ; Ardyan Prima WARDHANA ; Christina AVANTI
Clinical and Experimental Vaccine Research 2023;12(3):224-231
Purpose:
The Sinovac and AstraZeneca vaccines are the primary coronavirus disease 2019 vaccines in Indonesia. Antibody levels in vaccine-injected individuals will decline substantially over time, but data supporting the duration of such responses are limited. Therefore, this study aims to quantitatively evaluate antibody responses resulting from the completion of Sinovac and AstraZeneca administration in Indonesian adults.
Materials and Methods:
Participants were divided into two groups based on their vaccine type. Both groups were then assessed on the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (anti-SRBD) concentrations. The anti-SRBD level was measured using Elecsys anti-SARS-CoV-2 S assay and analyzed every month until 3 months after the second vaccination.
Results:
The results presented significant differences (p=0.000) in immunoglobulin G (IgG) titers among the vaccines’ measurement duration, where all samples observed a decrease in IgG titers over time. The mean titer levels of anti-SRBD IgG in the group given Sinovac were high in the first month after vaccination and decreased by 55.7% in 3 months. AstraZeneca showed lesser immune response with a slower decline rate. Adverse effects following immunization (AEFI) showed that systemic reactions are the most reported in both vaccines, with a higher percentage in the second dose of AstraZeneca type vaccines.
Conclusion
Sinovac induced more significant titers of anti-SRBD IgG 1 month after the second dose but generated fewer AEFIs. In contrast, AstraZeneca generated more AEFIs, in mild to moderate severity, but provided lower levels of anti-SRBD IgG.
2. Human Wharton's jelly mesenchymal stem cells inhibit cytokine storm in acute respiratory distress syndrome in a rat model
Wahyu WIDOWATI ; Teresa WARGASETIA ; Fanny RAHARDJA ; Rimonta GUNANEGARA ; Didik PRIYANDOKO ; Marisca GONDOKESUMO ; Ervi AFIFAH ; Cahyaning WIJAYANTI ; Rizal RIZAL ; Rizal RIZAL
Asian Pacific Journal of Tropical Biomedicine 2022;12(8):343-350
Objective: To evaluate the potential effect of human Wharton's jelly mesenchymal stem cells (hWJMSCs) on acute respiratory distress syndrome in lipopolysaccharide (LPS)-induced rats. Methods: The hWJMSCs (5×10 4 /mL, 5×10 5 /mL, 5×10 6 /mL) were administered to rats on day 1 and day 8 after being induced by LPS (5 mg/kg body weight). TNF-α levels in the lung and IL-18 and IL-1β levels in the serum were measured using ELISA. In addition, caspase-1 expression in lung tissues was quantified using qRT-PCR, and NF-κB and IL-6 expressions were assessed using immunohistochemistry. Results: The hWJMSCs decreased TNF-α levels in the lung and plasma IL-18 and IL-1β levels. Moreover, the hWJMSCs downregulated the expressions of caspase-1, IL-6, and NF-κB in lung tissues. Conclusions: The hWJMSCs can decrease inflammatory markers of acute respiratory distress syndrome in a rat model and may be further investigated for the treatment of acute respiratory distress syndrome.